Drug Targets for Prostate Cancer

Drug Targets for Prostate Cancer

Drug targets for Prostate cancer: pharmacology information

Drug targets for Prostate cancer: bioreagents

Drug Targets AR for Prostate Cancer with Approved Drugs

Drug targets Cancer drugs Company
AR enzalutamide Medivation

The androgen receptor (AR) plays a pivotal role in the normal growth and development of the prostate gland, and also in prostate carcinogenesis and progression to androgen-independent disease. Enzalutamide (formerly known as MDV3100) is a rationally designed, targeted androgen-receptor inhibitor that competitively binds to the ligand-binding domain of the androgen receptor and inhibits androgen-receptor translocation to the cell nucleus, recruitment of androgen-receptor cofactors, and androgen-receptor binding to DNA. In a phase 1–2 trial, enzalutamide was found to have encouraging antitumor activity in men with castration-resistant prostate cancer. (Beer T M, et al. Enzalutamide in metastatic prostate cancer before chemotherapy[J]. N Engl J Med, 2014, 2014(371): 424-433.)

Drug targets for Pancreatic cancer: Related Information